Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


12 Items
Title  Creator  Group name  Publishing year 
[2021 update of the GEFPICS' recommendations for HER2 status assessment in invasive breast cancer in France] Franchet et al. EquipeELC 2021-08-12
Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program Bertho et al. EquipePC 2021
Clinical practice guidelines for BRCA1 and BRCA2 genetic testing Pujol et al. EquipeCTCS 2021-03
[COVID-19 and people followed for breast cancer: French guidelines for clinical practice of Nice-St Paul de Vence, in collaboration with the Collège Nationale des Gynécologues et Obstétriciens Français (CNGOF), the Société d'Imagerie de la Femme (SIFEM), the Société Française de Chirurgie Oncologique (SFCO), the Société Française de Sénologie et Pathologie Mammaire (SFSPM) and the French Breast Cancer Intergroup-UNICANCER (UCBG)] Gligorov et al. EquipeCTCS 2020-05
Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2-14) Penault-Llorca et al. EquipeELC 2020-02
Analysis of the StoRM cohort reveals physical activity to be associated with survival in metastatic breast cancer Delrieu et al. EquipeCTCS 2020-07-01
[Breast cancer screening: On our way to the future] Delaloge et al. EquipeCTCS 09 2016
A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers Ferrari et al. EquipeMY 07 13, 2016
[Pre-analytical stage for biomarker assessment in breast cancer: 2014 update of the GEFPICS' guidelines in France] MacGrogan et al. EquipeELC Oct 2014
[2014 update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France] Penault-Llorca et al. EquipeELC Oct 2014
HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models Thomas et al. EquipeELC Aug 30, 2014
HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models Thomas et al. EquipeAP Aug 30, 2014
12 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés